RSS-Feed abonnieren

DOI: 10.1055/s-0044-1792091
Dengue and severe dengue with neurological complications: a challenge for prevention and control
Dengue e dengue grave com complicações neurológicas: um desafio para a prevenção e o controle
Abstract
Dengue is the main urban arbovirus in the Americas. The disease manifests in a varied spectrum: from asymptomatic cases to those with neurological involvement, which is considered a severe form of the disease. Its annual reemergence represents a serious public health problem. The rise in the number of cases causes an increase in the number of patients with neurological manifestations of the disease, which can range from headaches to more serious conditions such as encephalitis and Guillain-Barré syndrome, with high potential of death or sequelae. Dengue prevention and control strategies should also be a concern for neurologists. The aim of the present study is to carry out a narrative review of the current methods to prevent dengue fever and its severe forms, such as cases with neurological complications. The main control measures include vaccination, which is still carried out on a small scale, vector control, and individual protection. The CYD-TDV/Dengvaxia and TAK-003/DENVax vaccines, licensed for use by the Brazilian National Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, ANVISA, in Portuguese), show efficacy against hospitalizations of 72.7% (95% confidence interval [95%CI]: 62.3–80.3%) and of 90.4% (95%CI: 82.6–94.7%) respectively. The TV003/TV005 vaccine, which is being studied by Intituto Butantan in Brazil, shows promising results, with an efficacy of 79.6% for symptomatic dengue. Vector control is based on biotechnological and behavioral measures, as well as on the improvement of basic sanitation conditions. The main individual protection measure is the use of topical repellents (icaridin). All of these actions represent important tools for the prevention of dengue fever and its neurological complications.
Resumo
A dengue é a principal arbovirose urbana das Américas. A doença manifesta-se num espectro variado: desde casos assintomáticos até aqueles com envolvimento neurológico, que são considerados formas graves da doença. Sua reemergência anual representa um grave problema de saúde pública. O aumento do número de casos provoca o aumento do número de pacientes com manifestações neurológicas da doença, que podem variar de cefaleia a condições graves, como a encefalite e a síndrome de Guillain-Barré, com elevado potencial de morte ou sequelas. As estratégias de prevenção e controle da dengue também devem ser uma preocupação dos neurologistas. O objetivo deste estudo é fazer uma revisão narrativa dos métodos atuais de prevenção da dengue e das formas graves, como os casos com complicações neurológicas. As principais medidas de controle incluem a vacinação, que ainda é realizada em pequena escala, o controle do vetor e a proteção individual. As vacinas CYD-TDV/Dengvaxia e TAK-003/DENVax, aprovadas para uso pela Agência Nacional de Vigilância Sanitária (Anvisa), apresentam eficácia contra hospitalizações de 72,7% (intervalo de confiança de 95% [IC95%]: 62,3–80,3%) e de 90,4% (IC95%: 82,6–94,7%), respectivamente. A vacina TV003/TV005, que está sendo desenvolvida pelo Instituto Butantan no Brasil, apresenta resultados promissores, com uma eficácia de 79,6% para a dengue sintomática. O controle vetorial baseia-se em medidas biotecnológicas e comportamentais, assim como na melhoria das condições de saneamento básico. A principal proteção individual é o uso de repelentes tópicos (icaridina). Todas essas ações representam importantes ferramentas para a prevenção da dengue e das suas complicações neurológicas.
Palavras-chave
Dengue - Prevenção de Doenças - Vacinas - Controle de Vetores de Doenças - Repelentes de InsetosAuthors' Contributions
EOF: conceptualization, data curation, and writing – original draft; MPS: conceptualization, formal analysis, and writing – review & editing. All authors provided critical revision and approved the final version of the manuscript. All authors agreed on all aspects of the work.
Editor-in-Chief: Hélio A. G. Teive.
Associate Editor: Sérgio Monteiro de Almeida.
Publikationsverlauf
Eingereicht: 29. April 2024
Angenommen: 17. August 2024
Artikel online veröffentlicht:
03. Dezember 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Emanuelle de Oliveira Francelino, Marzia Puccioni-Sohler. Dengue and severe dengue with neurological complications: a challenge for prevention and control. Arq Neuropsiquiatr 2024; 82: s00441792091.
DOI: 10.1055/s-0044-1792091
-
References
- 1 Trivedi S, Chakravarty A. Neurological Complications of Dengue Fever. Curr Neurol Neurosci Rep 2022; 22 (08) 515-529
- 2 Conway MJ, Colpitts TM, Fikrig E. Role of the Vector in Arbovirus Transmission. Annu Rev Virol 2014; 1 (01) 71-88
- 3 World Health Organization. Dengue - Global situation. Accessed on April 02. 2024 . Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON498
- 4 Ministério da Saúde. Atualização de Casos de Arboviroses. Accessed on July 02. 2024 . Available at: https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/a/aedes-aegypti/monitoramento-das-arboviroses
- 5 Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Manual de Vigilância Sentinela de Doenças Neuroinvasivas por Arbovírus. 1st ed. Brasília:: Ministério da Saúde;; 2017: 44
- 6 Domingues RB, Kuster GW, Onuki-Castro FL, Souza VA, Levi JE, Pannuti CS. Involvement of the central nervous system in patients with dengue virus infection. J Neurol Sci 2008; 267 (1-2): 36-40
- 7 Mello CDS, Cabral-Castro MJ, Silva de Faria LC, Peralta JM, Puccioni-Sohler M. Dengue and chikungunya infection in neurologic disorders from endemic areas in Brazil. Neurol Clin Pract 2020; 10 (06) 497-502
- 8 Puccioni-Sohler M, Nascimento Soares C, Christo PP, Almeida SM. Review of dengue, zika and chikungunya infections in nervous system in endemic areas. Arq Neuropsiquiatr 2023; 81 (12) 1112-1124
- 9 Soares CN, Cabral-Castro M, Oliveira C. et al. Oligosymptomatic dengue infection: a potential cause of Guillain Barré syndrome. Arq Neuropsiquiatr 2008; 66 (2A): 234-237 ×2008000200018
- 10 Huang H, He X, Shi L. et al. Tanreqing injection inhibits dengue virus encephalitis by suppressing the activation of NLRP3 inflammasome. Chin Med 2024; 19 (01) 24
- 11 Palanichamy Kala M, St John AL, Rathore APS. Dengue: Update on Clinically Relevant Therapeutic Strategies and Vaccines. Curr Treat Options Infect Dis 2023; 15 (02) 27-52
- 12 Torres-Flores JM, Reyes-Sandoval A, Salazar MI. Dengue Vaccines: An Update. BioDrugs 2022; 36 (03) 325-336
- 13 Hadinegoro SR, Arredondo-García JL, Capeding MR. et al; CYD-TDV Dengue Vaccine Working Group. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med 2015; 373 (13) 1195-1206
- 14 Agência Nacional de Vigilância Sanitária (Anvisa). Anvisa aprova nova vacina contra a dengue. Accessed on March 22, 2024. Available at: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2023/anvisa-aprova-nova-vacina-para-a-dengue
- 15 Kallás EG, Cintra MAT, Moreira JA. et al. Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults. N Engl J Med 2024; 390 (05) 397-408
- 16 Mariz F. Jornal da USP. Vacina de dose única do Butantan contra dengue é segura e eficaz e seguirá para aval da Anvisa. Accessed on July 02, 2024. Available at: https://jornal.usp.br/ciencias/vacina-de-dose-unica-do-butantan-contra-dengue-e-segura-e-eficaz-e-seguira-para-aval-da-anvisa/
- 17 Buhler C, Winkler V, Runge-Ranzinger S, Boyce R, Horstick O. Environmental methods for dengue vector control - A systematic review and meta-analysis. PLoS Negl Trop Dis 2019; 13 (07) e0007420
- 18 Achee NL, Grieco JP, Vatandoost H. et al. Alternative strategies for mosquito-borne arbovirus control. PLoS Negl Trop Dis 2019; 13 (01) e0006822
- 19 World Health Organization (WHO). Eighteenth meeting of the WHO Vector Control Advisory Group: meeting report, 24-26 April 2023. Geneva: World Health Organization; 2023
- 20 Alphey L, McKemey A, Nimmo D. et al. Genetic control of Aedes mosquitoes. Pathog Glob Health 2013; 107 (04) 170-179
- 21 Dorigatti I, McCormack C, Nedjati-Gilani G, Ferguson NM. Using Wolbachia for Dengue Control: Insights from Modelling. Trends Parasitol 2018; 34 (02) 102-113
- 22 Pinto SB, Riback TIS, Sylvestre G. et al. Effectiveness of Wolbachia-infected mosquito deployments in reducing the incidence of dengue and other Aedes-borne diseases in Niterói, Brazil: A quasi-experimental study. PLoS Negl Trop Dis 2021; 15 (07) e0009556
- 23 Zimmermann IR, Alves Fernandes RR, Santos da Costa MG. et al Simulation-based economic evaluation of the Wolbachia method in Brazil: a cost-effective strategy for dengue control. Lancet Reg Health Am 2024; 35 (03) 100783
- 24 Sun R, Li M, McMeniman CJ, Akbari OS. CRISPR-Mediated Genome Engineering in Aedes aegypti. Methods Mol Biol 2022; 2509: 23-51
- 25 Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Articulação Estratégica de Vigilância em Sa. úde. Guia de Vigilância em Saúde. 5th ed. Brasília: Ministério da Saúde;; 2022. :1.126 p
- 26 Tedeschi CA, Galvão V, Ferraretto TRG, Pereira FAC. Avaliação dos repelentes: efeitos na saúde humana. Arq Ciênc Saúde UNIPAR 2023; 27 (05) 3168-3182
- 27 Clarkson TC, Janich AJ, Sanchez-Vargas I. et al. Nootkatone Is an Effective Repellent against Aedes aegypti and Aedes albopictus . Insects 2021; 12 (05) 386